Click here for international medical scientific information about Oncology for Healthcare Professionals.
Click here for general international information for patients, caregivers and the general public.
The annual WCLC meeting brings together the world’s largest gathering of lung cancer professionals.
Boehringer Ingelheim is dedicated to collaborating with the oncology community on a shared journey to deliver leading science. We will be holding a symposium on treatment sequencing for advanced non-small cell lung cancer (NSCLC), as well as presenting data highlighting recent findings in the treatment of lung cancer. Please see below for further details.
For more information on WCLC 2019, click here.
Join us at our WCLC symposium to hear an international faculty of experts discuss first-line treatment decisions for EGFR mutation-positive NSCLC, and second-line treatment decisions for advanced NSCLC, including squamous cell carcinoma and non-mutated, non-squamous disease.
Come and find out more about our emerging data during the scientific programme at WCLC.
Please revisit this page for further details about our poster presentations nearer the time of the congress.
Find out more about other oncology events
Click here to find out more about other oncology meetings, congresses, symposia and activities sponsored by Boehringer Ingelheim.
© 2019 Boehringer Ingelheim International GmbH. All rights reserved.
Page last updated: July 2019
Using this link will let you leave a website of Boehringer Ingelheim International GmbH (“BI”) or to a different domain under the control of BI. In the event that the linked site is not under the control of BI but under the control of a third party or an affiliate in the Boehringer Ingelheim group of companies, BI shall not be responsible for the contents, processing of personal data of any linked site or any link contained in a linked site, or any changes or updates to such sites. This link is provided to you only as a convenience, and the inclusion of any link does not imply endorsement by BI of the site.
Do you want to continue ?Continue